肿瘤细胞治疗研究
英文原题：Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer.
患者内脏转移灶消退（根据实体瘤疗效评价标准1.1版，总体部分缓解率为72%）；缓解在6个月时仍在持续。
一名患有进展性转移性胰腺癌的患者接受了单次输注16.2×10 9个自体T细胞，这些T细胞经过基因工程改造，能够克隆性表达两种针对肿瘤所表达的突变KRAS G12D的同种异体HLA-C*08:02限制性T细胞受体（TCR）。患者的内脏转移灶消退（根据实体瘤疗效评价标准1.1版，总体部分缓解率为72%）；缓解在6个月时仍在持续。细胞输注6个月后，工程化T细胞占所有循环外周血T细胞的2%以上。在该患者中，靶向KRAS G12D驱动突变的TCR基因治疗介导了转移性胰腺癌的客观缓解。（由Providence Portland Medical Foundation资助。）
A patient with progressive metastatic pancreatic cancer was treated with a single infusion of 16.2×10 9 autologous T cells that had been genetically engineered to clonally express two allogeneic HLA-C*08:02-restricted T-cell receptors (TCRs) targeting mutant KRAS G12D expressed by the tumors. The patient had regression of visceral metastases (overall partial response of 72% according to the Response Evaluation Criteria in Solid Tumors, version 1.1); the response was ongoing at 6 months. The engineered T cells constituted more than 2% of all the circulating peripheral-blood T cells 6 months after the cell transfer. In this patient, TCR gene therapy targeting the KRAS G12D driver mutation mediated the objective regression of metastatic pancreatic cancer. (Funded by the Providence Portland Medical Foundation.).
MEMBER ACCOUNT
登录成功会直接打开下一页。
